- Executive Management Team
- Product Specialist
Adam has a broad background in the pharmaceutical and biotechnology industries. He is a business developer and marketer with direct experience of drug and device development and the capital markets.
Previously, as Chief Business Officer at PowderMed, he led business development and commercial strategy which culminated in the successful sale of the company to Pfizer in late 2006, two and a half years after a series ‘A’ venture funding round.
Adam is also a Director at MGB Biopharma, another Archangels backed company in Scotland, focused on a new class of antibacterial drugs. His earlier career included roles in business development, marketing and R&D at PPL Therapeutics, GlaxoSmithKline, Abbott Laboratories and Schering AG, and as a City analyst at ABN Amro Hoare Govett. His educational background includes a BSc in Pharmacology from Southampton University and an MBA from Warwick Business School.
Bruce, with a Master’s degree in Immunology, has over 30 years’ experience within GLP and GMP licensed manufacturing facilities. As Operations Site Manager, he was previously responsible for all activities at Intercell’s cGMP vaccine manufacturing plant.
Prior to this Bruce held a number of senior management positions within the Biopharmaceutical Industry including Global Head of Quality and Qualified Person for Intercell (where he established and implemented quality and compliance systems to meet FDA, EMA and other international regulatory requirements) and senior management posts at Excell Biotech Ltd., and Serologicals (now part of Millipore) specialist Biologics manufacturers of cGMP medicinal products and medical devices.
Bruce is eligible to act as a Qualified Person under the permanent provisions of Directive 2001/82/EC and 2001/83/EC for both commercially licensed and investigational medicinal products.
Dr John Brown
Dr Brown has extensive experience in the life sciences sector. He is Chairman of the Cell and Gene Therapy Catapult and Senior Non-Executive Director of Acacia Pharma plc, and YourGene Health plc. Previously he was Chairman of Synpromics Ltd, Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd and CXR Biosciences Ltd and Senior Non-Executive Director of Quantum Pharma plc and Vectura Group plc.
In the public sector he is Chairman of the Roslin Foundation, a Fellow of the Royal Society of Edinburgh, and an Honorary Professor of the University of Edinburgh
Executive Management Team
Emma has extensive experience of all aspects of financial and business management acquired whilst working both in the UK and Europe. Emma started her career as a Graduate Trainee with The John Lewis Partnership where she gained valuable experience in financial control and management. She subsequently worked as Finance and Administration Manager (Central & Southern Europe) for British Rail International based in Basel, Switzerland but, with additional responsibility for the financial control of offices in Zurich and Milan.
Since returning to the UK, Emma has worked as Finance Director at Rocket Science UK Ltd and at the Scotch Malt Whisky Society before setting up her own business ‘Business Matters Scotland’ in 2005.
Emma has a Masters Degree in Business Administration (Passed with Distinction) from Edinburgh University and a B.Sc. (Hons) in Economic & Social History from the University of Bristol.
Executive Management Team
Qualified with a BSc in Biology, Marjory began her career in Contract Research, working with Inveresk Research International. Here she gained experience as Study Director / Project Manager, before moving to Syntex as Quality Assurance Auditor (GLP and GCP).
Marjory then moved in to industry, specialising in the medical device sector with Ethicon Ltd for over twenty years, where she gained experience in many aspects of R & D – focused on Clinical Research Management and Operations supporting and delivering high quality Clinical Studies.
Following her time with J & J, Marjory continued her career in medical device clinical research, both with her own company then with a global CRO, for over five years.
Executive Management Team
Steven, with a BA degree in Supply Chain Management, has over 20 years’ global operations experience in the life sciences, packaged consumer goods and electronics sectors. Steven has also worked as a consultant for several MedTech Startups and Glasgow University’s School of Engineering.
Prior to this Steven held several senior management positions in the UK and USA including Head of Supply Chain Operations at Alere Technologies responsible for the company’s cardiometabolic products (cardiac markers, glucose and HbA1C), CooperVision, Intercell and Bausch & Lomb. In addition to medical Steven has worked for several global blue-chip corporates including Motorola, IBM and Diageo.
Steven is a Certified Purchasing Manager (MCIPS) and a STEM careers advisor for his local high school. Before going into industry Steven was a fully qualified PGA Professional Golfer with 3 professional competition wins.
Alban is responsible for leading primary market research activities, driving marketing strategy formulation as well as forecasting. Prior to CALCiViS , Alban spent the past 10 years in various senior roles in advanced marketing analytics and international market research in the life sciences industries including pharmaceutical products, medical devices and dental technologies (CAD/CAM, radiology, dental implants and orthodontics).
Before his career in healthcare, he spent a decade leading product management in both the telecommunications and software industries as a Senior Software Product Manager for Lucent Technologies preceded by working as a Director of Marketing, Electronic Commerce Services for Bell Canada. He started his career at Bell Global Solutions as a Product Manager. He obtained a postgraduate degree in management from ESSCA (France) and a MSc from Concordia University (Canada) where he focused on advanced quantitative analytical methods and statistics.
Dr Chris Longbottom
Dr Christopher Longbottom was appointed Visiting Senior Research Fellow in the Dental Innovation and Translation Centre, Kings College London in April 2018, having previously retired from his role as Associate Director of the DITC at the end of 2017. Dr Longbottom worked in General Dental Practice in Scotland until 1974 when he joined the newly established Community Dental Service. In 1987 he was appointed as Lecturer in Paediatric Dentistry in Dundee Dental School, where he also worked closely with the Dental Health Services Research Unit, headed by Professor Nigel Pitts.
Dr. Chris Longbottom, first came upon the idea of using a luminescent photoprotein in relation to caries as he was flicking through a book called ‘Glowing Genes’ in 2005. He learnt that an agent had been developed that would produce luminescence in the presence of free calcium ions – as these ions are released from active caries lesions, he realised the potential application to aid caries diagnosis. Since that time, Dr. Longbottom has been part of a dedicated team of professionals who have advanced that concept, as well as the technology, to successfully launch the CALCIVIS® imaging system.
Mr. Peter Rees brings 23 years of experience in the dental and medical device sector. As VP and general manager of Dentsply Ltd, the company became the UK’s leading manufacturer of dental products. Latterly as Managing Director of ReeSearch, Peter was instrumental in launching a pharmaceutical product to the dental market.
He is a consultant and interim Chief Executive Officer of Hambley Ltd, a company specialising in the design and development of products for dental and medical industry. Mr. Rees holds a BSc (Hons) in Applied Biochemistry from the University of Liverpool John Moores and a Diploma in Dental Studies.
Dr Haroon is Chairman and General Partner of Julz Co (a US based fund) and a Director of CALCiViS. He brings over two decades of development and business development in medical device and pharmaceutical industry.
He has extensive transactional and M&A experience, both as direct lead and consultant, in venture and private equity held companies in health care industry. He has numerous board engagements and also maintains an appointment as Professor and Director at UNC Chapel Hill, NC.
Michael is President of Michael R. Crane & Associates, Ltd. (est 1999), a dental industry consulting firm providing a full range of business services. Prior to consulting Mr. Crane was an Officer and held senior positions at Dentsply International, Inc (Now Dentsply/Sirona, Charlotte NC USA), the world’s largest manufacturer of dental materials, equipment and instruments.
Mr. Crane held senior positions with Whaledent, J&J Dental and Ortho Pharmaceutical (Canada) Ltd and served on the Board of Ondine Biopharma, a Vancouver, Canada based Biotech Company together with Osspray Ltd., a UK biomaterials company, and start-up Navigate Surgical, in Vancouver.
Mr. Crane holds a Business degree from the University of British Columbia and resides in Vancouver, Canada.
Sarah Hardy – Observer
Sarah Hardy is the Chief Investment Officer at Archangels, Scotland’s leading business angel syndicate. She has extensive international experience of financing early stage opportunities in the technology sector, with specific focus on life science and healthcare.
She has managed a large portfolio of academic programmes, charitable organisations, SMES and larger companies (public and private), to add value and achieve a commercial exit. Before joining Archangels, Sarah worked in the Innovations Division of the Wellcome Trust, Advent Life Sciences venture team and Parke-Davis Neuroscience Research Centre. Sarah has a PhD in Molecular Neuropharmacology from the University of Aberdeen.
Veronica Tyrell – Observer
Dr Veronica Tyrrell is an Investment Manager with Scottish Enterprise, Scotland’s main economic, enterprise, innovation and investment agency managing a portfolio of investments across a range of sectors with experience.
An experienced Management Accountant Veronica was previously involved in assisting high growth companies from start up through to growth.